Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.39
−$0.05 · -3.47%
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Previous close
$1.39
−$0.05 · -3.47%
Regular session · ET · Market data may be delayed.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Day range
Current $1.39
52-week range
Current $1.39
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Sentiment
66
Bullish
Risk
70
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Day range
Current $1.39
52-week range
Current $1.39
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 200.86K USD | 337.49K USD | 408.03K USD | 435.2K USD | 681.61K USD |
| Gross profit | −200.86K USD | −337.49K USD | −408.03K USD | −435.2K USD | −681.61K USD |
| Research and development | 2.78M USD | 2.84M USD | 7.25M USD | 8.03M USD | 4.79M USD |
| Selling, general, and administrative | 5.79M USD | 6.45M USD | 8.79M USD | 11.5M USD | 20.47M USD |
| Operating expenses | 8.57M USD | 9.29M USD | 16.04M USD | 19.53M USD | 25.26M USD |
| Interest income | — | 219 USD | — | 5.25 USD | 10.32 USD |
| Interest expense | 106 USD | — | 3.71K USD | 5.25K USD | 10.32K USD |
| Depreciation and amortization | 200.86K USD | 337.49K USD | 408.03K USD | 435.2K USD | 681.61K USD |
| Operating income | −8.77M USD | −9.63M USD | −16.45M USD | −19.96M USD | −25.94M USD |
| Net income | −12.13M USD | −9.57M USD | −17.29K USD | −18.5M USD | −48.98M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
